Skip to content
by Legal Desire
17 August 2022

Latham & Watkins Advises on Halozyme Therapeutics, Inc.’s Upsized Private Offering of $625 Million of Convertible Senior Notes

Advising firms

Deal team

19 lawyers named
LawyerFirmSeniorityPracticeOffice
Cheston Larson Lead Latham & Watkins LLP Partner corporate San Diego
Michael Sullivan Lead Latham & Watkins LLP Partner corporate San Diego
Peter Simon Latham & Watkins LLP Associate corporate Not stated
Rachel Staub Latham & Watkins LLP Associate corporate Not stated
Alex Stuart-Lovell Latham & Watkins LLP Associate corporate Not stated
Greg Rodgers Latham & Watkins LLP Partner convertible debt New York
Andrew Blumenthal Latham & Watkins LLP Associate convertible debt Not stated
Andrew Bentz Latham & Watkins LLP Associate convertible debt Not stated
Ben Haas Latham & Watkins LLP Partner regulatory Washington, D.C.
Betty Pang Latham & Watkins LLP Counsel regulatory Bay Area
Chad Jennings Latham & Watkins LLP Associate regulatory Not stated
Steven Chinowsky Latham & Watkins LLP Partner intellectual property San Diego
Darryl Steensma Latham & Watkins LLP Counsel intellectual property San Diego
Robert Yeh Latham & Watkins LLP Associate intellectual property Not stated
Reza Mojtabaee-Zamani Latham & Watkins LLP Partner derivatives New York
Jack Neff Latham & Watkins LLP Associate derivatives Not stated
Hera Liao Latham & Watkins LLP Associate derivatives Not stated
Bora Bozkurt Latham & Watkins LLP Partner tax New York
Ted Gkoo Latham & Watkins LLP Associate tax Not stated

Stated terms

Stated value
USD 625m ($625.0 million)
What the figure measures
Issue size
Client
Halozyme Therapeutics, Inc.Issuer
Counterparties
initial purchasers (Underwriters)